Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Youcare Pharmaceutical Group Co. Ltd.

Latest From Youcare Pharmaceutical Group Co. Ltd.

Divergent Progress For Chinese Developers Of COVID Antivirals, Vaccines

Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.

China Coronavirus COVID-19

Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19

China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.

China Coronavirus COVID-19

China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?

CSPC acquires a little-known Guangzhou biotech to kick-start China's pharma sector consolidation in 2022, a key goal outlined in the country's recent 14th Five-Year Plan.

China Deals

China Plans To Speed Up Pharma Consolidation By 2025

China's new five-year plan for the pharma sector calls for closer collaboration between large and small domestic pharma companies, not only for products and technologies but also capital. However, it remains to be seen which specific measures government agencies will take to achieve the broad goals.

China Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals